HomeNewsBusinessToo many top level exits in Cognizant in the last one year. Here's why

Too many top level exits in Cognizant in the last one year. Here's why

The company had seen at least half a dozen top level exits and termination of thousands of mid and senior employees since Brian Humphries took over

July 11, 2020 / 18:56 IST
Story continues below Advertisement

In a surprise development on July 9, NASDAQ-listed Cognizant’s India head Ramkumar Ramamoorthy quit after a 23 years stint. He had only taken over as the India chief on September 2019.

Of course, it is hardly an isolated event as the company has been witness to a series of top level exits since Brian Humphries became the CEO starting April 1, 2019.

Story continues below Advertisement

There are several obvious reasons. “The executive churn is inevitable in any company whenever a new CEO takes charge. Most executives who left had been with the firm for close to 15-20 years, i.e. since the time of Francisco D’Souza,” said Pareekh Jain, founder, Pareekh Consulting, a tech consultancy firm.

With the pressure to perform and Humphries’ focus to bring back growth in Cognizant, there was an immense pressure to perform. In addition, Humphries took drastic measures to cut down costs and focus on growth.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show